

ACCREDITATION DOCUMENT

F-06/02

Issue Date: 18/08/2020

Rev. No: 09 LAB 291

Accreditation No: LAB 291

Awarded to

Quality Control Laboratory PharmEvo (Pvt.) Limited Plot No. A-29, North Western Industrial Zone, Port Qasim, Karachi-75020, Pakistan.

The scope of accreditation is in accordance with the standard specifications outlined in the following page(s) of this document. The accredited scope shall be visible and legible in areas such as customer service, sample-receiving section etc. and shall not mislead its users.

The accreditation was first time granted on **25-07-2023** by Pakistan National Accreditation Council.

The laboratory complies with the requirements of ISO/IEC 17025:2017.

The accreditation requires regular surveillance, and is valid until 24-07-2026.

The decision of accreditation made by Pakistan National Accreditation Council implies that the organization has been found to fulfill the requirements for accreditation within the scope.

The organization however, itself is responsible for the results of performed measurements/tests.

PAKISTAN NATIONAL ACCREDITATION COUNCIL

25-07-2023	SD	
Date	Director General	



ACCREDITATION DOCUMENT

F-06/02

Issue Date: 18/08/2020

Rev. No: 09 LAB 291

Testing Laboratory.

Accreditation Scope of Quality Control Laboratory of M/s PharmEvo (Pvt.) Limited Plot No. A-29, North Western Industrial Zone, Port Qasim, Karachi-75020, Pakistan.

Permanent laboratory premises X

Materials/Prod ucts tested	Testing field (e.g. environmental testing or mechanical testing)	Types of test/ Properties measured /technique	Reference to standardized method (e.g. ISO 14577- 1:2003)/ Internal method reference
X-plended Tablet 5mg	Chemical	Assay	Assay 2022 USP monograph ;<621>
		Dissolution	Dissolution 2021 USP monograph ;<711>
	Chemical	Assay	Assay 2022 USP monograph ;<621>
X-plended Tablet 10mg		Dissolution	Dissolution 2021 USP monograph ;<711>
	Chemical	Assay	Assay 2022 USP monograph ;<621>
X-plended Tablet 20mg		Dissolution	Dissolution 2021 USP monograph ;<711>